Introduction
============

Kawasaki disease (KD) is an acute inflammatory vasculitis of the medium- and small-sized arteries generally occurring in children under 5 years old. It was first described by [@B23] associated with the development of coronary artery aneurysms (CAA) or ecstasies in 15--25% of untreated children. Coronary lesions may lead to ischemic heart disease and sudden death. The etiopathology of KD remains unknown though it is widely accepted that it results in an important inflammation cascade triggered by unknown infectious or other stress trigger in a genetically predisposed individual. A single infusion of 2 g/kg of intravenous immunoglobulins (IVIGs) along with aspirin is the standard treatment for KD but not all children may respond, especially the youngest ones and those predisposed to develop CAA. Interleukin 1 (IL-1) cytokine has been shown to play a key role in the development of CAA leading to a potential use of IL-1 blockade in patients with KD.

Kawasaki Disease
================

Classically, KD is diagnosed in the presence of high fever lasting for at least 5 days associated to at least four principal features (**Table [1](#T1){ref-type="table"}**). No blood tests are available for diagnosis of KD, therefore, a clinical algorithm has been established and validated by the American Academy of pediatrics (**Table [1](#T1){ref-type="table"}**) ([@B33]). In some cases, KD diagnosis can be made at day 4 of illness in the presence of ≥4 principal criteria. Some patients have incomplete KD, especially infants ≤6 months. In this situation, KD diagnosis is challenging and should be looked for in infants with ≥7 days of fever without explanations, even though no KD clinical criteria are found. In this case, children should, therefore, undergo laboratory testing and, if any systemic inflammation is found, an echocardiogram should be performed ([@B33]). Echocardiographic evaluation should be performed at the time of diagnosis, at 2 weeks and at 6--8 weeks after onset of the disease. More frequent echocardiographic evaluation is needed in children at higher risk ([@B33]). Kawasaki disease vasculitis may occur outside the heart in other medium-sized vessel such as axillary, renal and femoral arteries somewhat difficult to distinguish from infantile periarteritis nodosa ([@B7]).
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Kawasaki disease (KD) clinical algorithm ([@B33]).
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Treatment in KD
---------------

A single infusion of 2 g/kg of IVIG along with aspirin has reduced CAA frequency from 25 to 5%. However, 10--20% of patients do not respond to standard treatment and have an increased risk of cardiac complications and death.

Corticosteroids (CS) as well as anti-tumor necrosis factor (TNF) agents are the two main treatments used in IVIG-resistant patients ([@B15]). Although there are no formal recommendations regarding optimal CS doses and duration ([@B12]), CS has not shown significant differences compared to an additional IVIG treatment in terms of preventing the development of CAA ([@B31]; [@B34]). The elevated level of TNF-α in the sera of KD patients correlated with CAA development has led to the use of anti-TNF agent ([@B15]). The most frequently used is infliximab (IFX), a chimeric murine/human IgG1 monoclonal antibody that binds to TNF-α. This treatment has been administered in IVIG-resistant patients with success regarding fever and inflammatory parameters, however, with no differences regarding cardiac disease ([@B9], [@B6]; [@B41]). Other immunosuppressive agents have occasionally been used such as: cyclosporine, cyclophosphamide, methotrexate, and plasma exchange in resistant KD patients to IVIG, steroids, and anti-TNFα ([@B19]).

Although the use of different treatments has changed KD outcome, this disease is still lethal in certain cases. The individual prognostic factors are still poorly defined, and resistance to standard therapy represents a major risk of cardiac complications. Developing more efficient treatments and with a better action on cardiac involvement seems a priority. The phenotypical similarities between KD and systemic autoinflammatory disease (SAID) led researches to look at the role of inflammatory cytokines namely IL-1 in KD.

Why to Use IL-1 Blockade in KD?
-------------------------------

### KD and Systemic Juvenile Idiopathic Arthritis (SJIA): Is There a Missing Link?

Kawasaki disease and SJIA represent a major cause of fever of unknown origin in young children and share intriguing similarities. Clinically, both diseases present with high fever, macular rashes, myalgia, arthralgia, and adenopathy although arthritis seems to be specific to SJIA ([@B26]); for this reason, it is difficult to differentiate KD from early SJIA especially when KD is incomplete. Early age of presentation seems to favor KD. Moreover, cardiac abnormalities have been described, especially serositis as in many SAID. Unlike KD, SJIA coronary lesions are mild (essentially hyper echogenic coronaries) with favorable evolution; no CAA are described. Because of CAA risk in incomplete KD and need for early treatment, many patients with SJIA may be initially treated as KD, with IVIG and aspirin, but without efficacy ([@B26]). Looking at laboratory findings, no differences can be seen. Both present elevated C-reactive protein, leukocytosis, thrombocytosis, hypoalbuminemia, anemia, and even macrophage activation syndrome (MAS) ([@B26]). Assumptions have been made that these two systemic inflammatory disorders could share common triggering agents, susceptibility factors, or immunopathogenic pathways.

When looking at sera of KD and SJIA patients, inflammatory cytokines such as IL-1, IL-6, TNF-α, and interleukin-18 (IL-18) are increased. IL-18 being specifically higher in SJIA compared to KD patient ([@B32]). These phenotypical similarities between KD and SJIA along with the immunological features led to the hypothesis that KD could be considered as an SAID as SJIA and cryopyrin-associated periodic syndrome (CAPS) ([@B1]).

### IL-1 Signature in SJIA and KD:

Inflammatory cytokines, especially IL-1β, has first been described as markedly increased in SAID such as CAPS and SJIA ([@B21]). CAPS has allowed to understand the key role of IL-1 in the disease pathogenesis and showed striking response to IL-1-blocking therapies ([@B42]). NLRP3 is a nod-like receptor (NLR) that is part of an inflammasome, which activates the caspase-1 (CASP1) and consequently the secretion of active IL-1β and IL-18 ([@B2]). *NLRP3* gene mutations result in constitutive activation of the NLRP3 protein and in an amplification loop of inflammation in which normal regulatory systems, i.e., ATP and second signal requirement are debrided, and where the pro IL-1β may act itself as a danger signal ([@B24]).

More recently, IL-1 has been shown to play a critical role in the pathogenesis of SJIA. [@B35] showed three major results. First, serum from SJIA patients induces the transcription of innate immunity genes including IL-1 in peripheral blood mononuclear cells (PBMCs) from healthy volunteers. Second, when activating PBMCs of SJIA patients, a large amount of IL-1β is released. Finally, they showed that, the use of recombinant IL-1 receptor antagonist (IL1-RA) (anakinra) allowed complete clinical remission in seven of the nine refractory-treated patients thus, emphasizing the central role of the innate immune system (IIS), and specifically, inflammasome-derived cytokines, in the pathogenesis of SJIA ([@B35]).

As in systemic diseases, IL-1 seems to play a key role in the physiopathology of KD and more importantly in cardiac involvement for various reasons. [@B1] showed a significant increased level of IL-1β, IL-18 and of their antagonists (IL-1RA and IL-18BP) in acute KD patients compared with age-matched control patients with viral or bacterial infections. Moreover, IL-1-induced inflammation has been shown to play a role in acute myocardial infarction and contributes to acute ischemic diseases. Indeed, IL-1 is known to enhance the expansion, differentiation and migration of antigen-specific CD8+ T cells as well as the induction of matrix enzymes source of major tissue damage. In the heart and brain, this inflammation can be fatal ([@B29]). In KD, antigen-driven CD8+ T cells are known to infiltrate the coronary artery wall and contribute to the pathogenesis of CAA ([@B4]). The assumption appears all the more justified when looking at IVIG mechanism on inflammatory cytokines. In responsive KD patients treated with IVIG therapy, the level of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) are decreased emphasizing immunoglobulin's (IG) effect on the modulation of inflammatory cytokines namely on IL-1. Although the way IVIG acts is not perfectly understood, it is known to reduce CAA prevalence ([@B18]).

Interleukin-1 polymorphisms could be associated either to response or resistance to IVIG treatment ([@B44]). Interestingly elevated transcripts have been shown in IVIG-resistant KD patients, which carry the highest risk for coronary aneurysms ([@B17]). Increased transcript abundance of the neutrophil-associated calcium-binding proteins, S100A8 and A9, confirms the role of activated neutrophils in acute KD, as these proteins regulate adhesion of neutrophils and monocytes to the endothelial cell, a critical process in KD vasculitis. S100A8/9 proteins are elevated in patients who develop coronary aneurysms. The S100A8/9 heterodimer is known to activate the IL-1 receptor-associated kinase and the NF-~κ~B. S100A8/9 appears to be useful biomarkers for identifying IVIG-resistant patients. Other markers of endothelial cell activation CEACCAM1 (carcino embryonic antigen-related cell adhesion) and VEGF (vascular endothelial growth factor) have been detected in acute KD and may correlate with IGIV resistance and coronary vasculitis ([@B44]).

The role of IIS in the histopathology of KD has also been shown *in vivo* in mice.

Mouse Model of CAA- and IL-1-signaling Pathways
-----------------------------------------------

A mouse model of coronary arteritis has been developed using intraperitoneal injection of *Lactobacillus casei* cell-wall extract (LCCWE). This mouse develops a focal, localized coronary arteritis that histopathologically mimics the coronary artery lesions found in human KD ([@B28]). As in human CAA, the coronary lesions of LCCWE contains macrophages, activated dendritic cells, and T cells ([@B39]). Moreover, the CAA in LCCWE mice responds to IVIG therapy as in KD children ([@B27]). Although both innate and adaptive immunity have been shown as essential for the development of CAA in the LCCWE mouse model, IIS seems to play a key role. Two cytokines have been described as important in the development of CAA: NF-κB and IL-1. [@B36] have pointed out the role of toll-like receptors (TLRs), a major sensor of IIS, in KD inflammation and therefore in CAA. In LCCWE, NF- NF-κB, an inflammatory cytokine, is activated and synthesized after activation of TLR-2 using a MyD88-dependent pathway ([@B36]). NF-κB activation coordinately controls both the innate and adaptive immune responses. To induce vasculitis in LCCWE mice, TLR2 are required as IL-1R signaling highlighting, amongst others, the importance of IL-1-signaling pathway in vasculitis ([@B36]). Both IL-1α and IL-1β have been shown to induce aneurysm formation in LCCWE mouse model of KD; aneurysm that are successfully improved with IL-1 blocker treatment such as anakinra ([@B38]). Similar successful results were reported in recalcitrant KD children using IL-1 blockade ([@B1]).

[@B25] presented a mouse model of a knock-out LCCWE mouse (CASP1-/- and IL-1R-/-) in whom KD finally developed after injection of recombinant IL1-β protein. This mouse developed coronary arteritis, which could be prevented by injection of the IL-1 receptor antagonist (IL-1RA): anakinra, during 3--5 days. Using the LCWE mouse model, a logical progression of experiments demonstrated that (i) bone marrow-derived macrophages secrete high levels of IL-1β and TNFα; (ii) IL-1β is processed from pro-IL-1β by CASP1 through the NLRP3 inflammasome; (iii) exogenous treatment with IL-1β recreates the inflammatory phenotype in CASP1 deficient mice; and (iv) IL-1R-deficient mice or mice treated with the recombinant IL-1RA, anakinra fail to develop the arteritis lesions. Of particular note, only blockade of IL-1β, but not blockade of TNF-α, reduced the myocarditis in the LCWE-injected mice ([@B5]; [@B25]). A recent case report showed a dramatic effect on rescuing a life-threatening case of relapsing KD ([@B13]).

Genetics: IL-1 Pathway and Calcium Signaling
--------------------------------------------

Finally, analysis of the whole-genome expression profile of acute KD patients has pointed out the importance of IL-1β activation in KD inflammatory profile by showing the link between calcium concentration and inflammasome.

Inositol-triphosphate 3-kinase C (ITPKC) is a candidate gene located on chromosome 19q13.2 whose CC genotype is implicated as a determinant of both disease susceptibility and outcome in KD. ITPKC phosphorylates inositol 1, 4, 5-triphosphate (IP3) to inositol 1, 3, 4, 5-tetraphosphate (IP4), therefore, regulating the calcium response to extracellular signals. At the same time, NLRP3 inflammasome has been shown to be dependent of both extracellular and intracellular calcium concentration (\[Ca^2+^\]i). Amazingly, ITPKC CC genotype is associated with both highest basal and stimulated \[Ca^2+^\]i levels and increased amounts of NLRP3 protein compared with other genotypes at baseline. These findings, allowed making the hypothesis of a link between the calcium level and the activation of NLRP3 in ITPKC CC genotype leading to an excess of IL-1 secretion as in SAID. Moreover, ITPKC CC genotype is associated with failure of IVIG therapy ([@B1]). This emphasizes the fact that phenotypic similarities between KD and AID are anchored by the common immunobiological processes associated with inflammasome activation.

Experience of IL-1 Blockade in KD Patients
------------------------------------------

Nowadays, three IL-1 blockades have been approved: anakinra, rilonacept, and canakinumab. Anakinra (Kineret^®^) was the first IL-1 blockade agent administered initially in rheumatoid arthritis (1993) and is now used in numerous diseases such as hereditary SAIDs ([@B38]). It is an IL1-RA blocking both IL-1α and IL-1β ([@B10]). In 2008, rilonacept ([@B22]), a soluble IL-1 decoy receptor, that neutralizes either IL-1α or IL-1β, received US Food and Drug Administration (FDA) approval in CAPS patients, and Canakinumab (Ilaris^®^) in 2009 ([@B11]). The latter is a humanized monoclonal antibody that specifically blocks IL-1β ([@B14]). In pediatrics, only anakinra (≥8 months and 10 kg) and canakinumab (≥24 months and ≥7.5 kg) have FDA and European Medicines Agency (EMA) approval for CAPS disease. These IL-1 blockades are safe and well tolerated with a low-adverse event rate ([@B37]). Anakinra is preferred for it has a remarkable record of safety with over 150,000 patients treated daily for over 10 years ([@B3]; [@B16]). In addition, drug level significantly drops 1 h after discontinuation of treatment ([@B14]).

In SJIA, the three IL-1 blockers have been tested so far and were proven as effective and safe, although only canakinumab is currently approved for use ([@B20]). In addition, anakinra has been demonstrated as efficient in severe SJIA with MAS ([@B30]) a severe complication that can occur in up to half of SJIA patients. In KD, MAS is probably a frequently under-recognized complication situation which could benefit from IL-1 blockers ([@B43]).

For now, two case reports showing promising results with anakinra in severe KD patient have been published. The first one is an 11-week-old Caucasian female that presented with severe KD complicated by MAS. Diffuse enlargement of the entire coronary artery system was revealed by echocardiogram. IVIG, aspirin and CS were inefficient. High doses of anakinra (3 mg/kg/dose, twice daily for 3 days) were introduced at day 6 because of bad clinical outcome and biological signs of MAS. IFX and methylprednisolone were added at day 9 because of cardiac failure despite favorable clinical and biological course. The evolution was favorable allowing CS to be tapered off over 10 days following discharge and under anakinra over the next 5 months. At 8 months, the echocardiogram was normal ([@B40]).

The second one is a 2-year-old boy diagnosed with KD who developed secondarily cardiac failure (shortening fraction of 20%) without CAA under IVIG (2 g/kg) treatment. A second IVIG perfusion was administered as well as multiple methylprednisolone pulses with little effect and worsening of cardiac involvement. Extracorporeal membrane oxygenation was performed from day 14 until day 17 and subcutaneous anakinra (1 mg/kg/day) was introduced at day 18 until day 24 with success. Relapse was seen three days after anakinra's last injection with progression to giant CAA. Anakinra was therefore reinitiated for 6 weeks with normalization of the coronary lesions at 6 months ([@B13]).

What Could Be the Place of Anti-IL1 in the Current Standard of KD Treatments?
-----------------------------------------------------------------------------

Considering current knowledge, it seems reasonable to use IL-1 blockade in resistant KD with CAA before IFX which has not proven its efficiency in coronary disease. A new approach could be the early use of IL-1 blockade associated with CS in patients at high risks of severe KD depending on validated risk scores, in Japanese patients. Apart from IVIG's, anti-IL1 are the only therapies that have proven their effect on CAA. It should be considered whether their use should not be generalized to all patients. Indeed, IL-1 blockers seem to better prevent CAA development than IVIG, especially if used at diagnosis. In this idea three clinical trials of IL-1 blockade enrolling KD patients are currently being conducted in Western Europe and in the US (**Table [2](#T2){ref-type="table"}**) ([@B8]). Their conclusion may help to better define, in the future, the place of IL-1 blockade in KD treatment in association or in replacement of IGIV and CS.

###### 

Clinical trials of IL-1 blockade enrolling KD patients conducted in Western Europe and in USA ([@B8]).

  Name                                                        Type of trial                                                                         IL-1 blockade/Doses                                                                                                                                                                                                Population KD patients                                                                                         Objective                                                                                                                                                     Time
  ----------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------
  Kawakinra trial (Europe) (Eudract Number: 2014-002715-41)   Phase IIa, multi-centered trial                                                       Anakinra: 2 mg/kg/day Dose can be increased by 2 mg/kg/24 h if persistent or recrudescent fever (max 6mg/kg/d)                                                                                                     Children: 8 months (≥10 kg)--18 years Screened: 4th--13th day of fever                                         Primary end points Efficacy and safety of anakinra Secondary objectives Effects of anakinra on coronary artery Disease activity and inflammation biomarkers   14 days of treatment
  Anakid trial (USA) (clinicaltrials.gov\#NCT02179853)        Phase I/IIa study: Two-centered and dose escalation trial                             Anakinra: 2, 4 or 8 mg/kg Persistent or recrudescent fever after ≥36 h and \<7 days following the end of intravenous immunoglobulin (IVIG) infusion                                                                Children (≥8-M -old) with acute KD and with coronary artery (*Z*-score ≥3.0 in the RCA or LAD) abnormalities   Safety, tolerability, and pharmacokinetics of anakinra                                                                                                        2--6 weeks
  Canakinumab trial (Europe)                                  Phase II trial: Two-arm, multi-centered and carried out in seven European countries   Canakinumab: 6 mg/kg IV Group 1: Complete fever resolution Canakinumab (1 or 2 SC injections) at 4 and 8 weeks Depending on the clinical and CRP course Group 2 Fever remains after 48--72 h of canakinumab IVIG   Naïve KD patients or IVIG-resistant KD patient                                                                 The presence or absence of fever will be looked-for.                                                                                                          

IVIG, intravenous immunoglobulin; RCA: right coronary artery; LAD, left anterior descending coronary artery; SC, subcutaneous.

Conclusion
==========

Kawasaki disease clinical and immunological features mimic SAID. These similarities have allowed looking at new inflammatory cytokines such as IL-1. Better understanding of IL-1 involvement in KD and specifically in CAA with the use of IL-1 blockers, has brought hope for resistant and severe patients. Doses and time to introduce IL-1 therapy has still to be defined. Another challenge is the need to better define patients with a higher risk of CAA, allowing better medical care and the use of new treatment strategies. We hope that results of clinical trials using IL-1 blockade will allow to better understand the respective roles of IL-1α and β, and to pursue with phase III trials.
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